Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology - United Kingdom
doi 10.1002/hon.96_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Outcomes of Patients With Large B‐Cell Lymphomas and Progressive Disease Following CD19‐Specific CAR T‐Cell Therapy

American Journal of Hematology
Hematology
2019English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before Cd19 Car T Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rapid Relapse of Large B‐Cell Lymphoma After CD19 Directed CAR‐T‐Cell Therapy Due to CD‐19 Antigen Loss

American Journal of Hematology
Hematology
2019English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy